Journal article
Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies in Australia after the First Epidemic Wave in 2020: A National Survey
KM Vette, DA Machalek, HF Gidding, S Nicholson, MVN O'Sullivan, JB Carlin, M Downes, L Armstrong, FH Beard, DE Dwyer, R Gibb, IB Gosbell, AJ Hendry, G Higgins, R Hirani, L Hueston, DO Irving, HE Quinn, H Shilling, D Smith Show all
Open Forum Infectious Diseases | Published : 2022
DOI: 10.1093/ofid/ofac002
Abstract
Background: As of mid-2021, Australia's only nationwide coronavirus disease 2019 (COVID-19) epidemic occurred in the first 6 months of the pandemic. Subsequently, there has been limited transmission in most states and territories. Understanding community spread during the first wave was hampered by initial limitations on testing and surveillance. To characterize the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody seroprevalence generated during this time, we undertook Australia's largest national SARS-CoV-2 serosurvey. Methods: Between June 19 and August 6, 2020, residual specimens were sampled from people undergoing general pathology testing (all..
View full abstractGrants
Awarded by Australian Government Department of Health
Awarded by Snow Medical Foundation
Awarded by Australian Partnership for Preparedness Research on Infectious Disease Emergencies Centre for Research Excellence (APPRISE CRE)
Funding Acknowledgements
This study was funded by Australian Government Department of Health (HEALTH/20-21/E20-156381; Snow Medical Foundation (CT28701/G207593); and the Australian Partnership for Preparedness Research on Infectious Disease Emergencies Centre for Research Excellence (APPRISE CRE, APP1116530). Australian governments fund Australian Red Cross Lifeblood for the provision of blood, blood products, and services to the Australian community.